$2.51T
Total marketcap
$202.54B
Total volume
BTC 50.10%     ETH 15.71%
Dominance

Cerevel Therapeutics CERE Stock

42.56 USD {{ price }} 0.543349% {{change_pct}}%
Exchange
NasdaqCM
Market Cap
7.73B USD
LOW - HIGH [24H]
42.35 - 42.8 USD
VOLUME [24H]
2.55M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.67 USD

Cerevel Therapeutics Price Chart

Cerevel Therapeutics CERE Financial and Trading Overview

Cerevel Therapeutics stock price 42.56 USD
Previous Close 34.17 USD
Open 33.97 USD
Bid 0 USD x 800
Ask 0 USD x 1400
Day's Range 33.93 - 35.59 USD
52 Week Range 22.63 - 41.46 USD
Volume 958.61K USD
Avg. Volume 567.97K USD
Market Cap 5.55B USD
Beta (5Y Monthly) 1.47912
PE Ratio (TTM) N/A
EPS (TTM) -2.67 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 36.33 USD

CERE Valuation Measures

Enterprise Value 5.16B USD
Trailing P/E N/A
Forward P/E -12.5461
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 12.846769
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -13.24

Trading Information

Cerevel Therapeutics Stock Price History

Beta (5Y Monthly) 1.47912
52-Week Change 47.90%
S&P500 52-Week Change 20.43%
52 Week High 41.46 USD
52 Week Low 22.63 USD
50-Day Moving Average 30.51 USD
200-Day Moving Average 29.18 USD

CERE Share Statistics

Avg. Volume (3 month) 567.97K USD
Avg. Daily Volume (10-Days) 545.72K USD
Shares Outstanding 156.83M
Float 59.07M
Short Ratio 9.01
% Held by Insiders 17.55%
% Held by Institutions 88.81%
Shares Short 5.02M
Short % of Float 11.38%
Short % of Shares Outstanding 3.20%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -31.86%
Return on Equity (ttm) -81.30%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -389763008 USD
Net Income Avi to Common (ttm) -387503008 USD
Diluted EPS (ttm) -2.73
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 826.99M USD
Total Cash Per Share (mrq) 5.27 USD
Total Debt (mrq) 438.71M USD
Total Debt/Equity (mrq) 101.62 USD
Current Ratio (mrq) 13.355
Book Value Per Share (mrq) 2.754

Cash Flow Statement

Operating Cash Flow (ttm) -320462016 USD
Levered Free Cash Flow (ttm) -179429872 USD

Profile of Cerevel Therapeutics

Country United States
State MA
City Cambridge
Address 222 Jacobs Street
ZIP 02141
Phone 844 304 2048
Website https://www.cerevel.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 319

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Q&A For Cerevel Therapeutics Stock

What is a current CERE stock price?

Cerevel Therapeutics CERE stock price today per share is 42.56 USD.

How to purchase Cerevel Therapeutics stock?

You can buy CERE shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Cerevel Therapeutics?

The stock symbol or ticker of Cerevel Therapeutics is CERE.

Which industry does the Cerevel Therapeutics company belong to?

The Cerevel Therapeutics industry is Biotechnology.

How many shares does Cerevel Therapeutics have in circulation?

The max supply of Cerevel Therapeutics shares is 181.58M.

What is Cerevel Therapeutics Price to Earnings Ratio (PE Ratio)?

Cerevel Therapeutics PE Ratio is now.

What was Cerevel Therapeutics earnings per share over the trailing 12 months (TTM)?

Cerevel Therapeutics EPS is -2.67 USD over the trailing 12 months.

Which sector does the Cerevel Therapeutics company belong to?

The Cerevel Therapeutics sector is Healthcare.

Cerevel Therapeutics CERE included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD